公开(公告)号：US20240197753A1

公开(公告)日：2024-06-20

申请号：US18283585

申请日：2022-03-25

申请人： OSAKA UNIVERSITY ,  CUORIPS INC.

发明人： Yoshiki SAWA ,  Shigeru MIYAGAWA ,  Yoshiki SAKAI ,  Yasuhiro YANAGI

IPC分类号： A61K31/559 ,  A61K9/06 ,  A61K9/16 ,  A61K9/70 ,  A61K47/42 ,  A61P9/04

CPC分类号： A61K31/559 ,  A61K9/06 ,  A61K9/1647 ,  A61K9/7007 ,  A61K47/42 ,  A61P9/04

摘要： An object is to provide a pharmaceutical composition that improves cardiac function when administered during coronary artery bypass surgery for ischemic cardiomyopathy. A pharmaceutical composition for improving cardiac function comprising: (A) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin 12 receptor agonist, the PLGA having an average molecular weight of 10000 to 30000; and (B) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin 12 receptor agonist, the PLGA having an average molecular weight of 40000 to 60000.

公开(公告)号：US11896600B2

公开(公告)日：2024-02-13

申请号：US17026263

申请日：2020-09-20

申请人： Kodimule Shyam Prasad

发明人： Kodimule Shyam Prasad

IPC分类号： A61K31/559 ,  A61K31/4045 ,  A61K36/74 ,  A61P25/28 ,  A61K9/00 ,  A61K31/522 ,  A61K31/216

CPC分类号： A61K31/559 ,  A61K31/4045 ,  A61K36/74 ,  A61P25/28 ,  A61K9/0053 ,  A61K31/216 ,  A61K31/522

摘要： The invention provides a composition comprising one or more hydroxytryptamides and method of its use in the treatment of neurodegenerative disorders. The invention includes embodiments wherein the composition comprises caffeine and chlorogenic acids. The composition finds use in the treatment of Alzheimer's disease and Parkinson's disease, including providing neuroprotection against the advancement of the symptoms of these disorders.

公开(公告)号：US20190247365A1

公开(公告)日：2019-08-15

申请号：US16391907

申请日：2019-04-23

申请人： Cumberland Pharmaceuticals Inc.

发明人： Leo PAVLIV ,  Martin OGLETREE

IPC分类号： A61K31/422 ,  A61K31/559

CPC分类号： A61K31/422 ,  A61K31/559

摘要： The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof. The present invention is also directed to methods of treating hepatic encephalopathy and cerebral edema by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof.

公开(公告)号：US20170348214A1

公开(公告)日：2017-12-07

申请号：US15409494

申请日：2017-01-18

申请人： Duke University

发明人： Mitchell A. deLong ,  John M. McIver ,  Robert S. Youngquist

IPC分类号： A61K8/49 ,  A61K45/06 ,  A61K31/559 ,  A61K31/5575 ,  A61K31/381 ,  A61K8/365 ,  A61K31/192 ,  A61K31/19 ,  A61K8/37 ,  A61Q7/00 ,  A61K31/428

CPC分类号： A61K8/49 ,  A61K8/365 ,  A61K8/37 ,  A61K8/4986 ,  A61K31/19 ,  A61K31/192 ,  A61K31/381 ,  A61K31/428 ,  A61K31/5575 ,  A61K31/559 ,  A61K45/06 ,  A61Q7/00

摘要： A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.

公开(公告)号：US20170281613A1

公开(公告)日：2017-10-05

申请号：US15627238

申请日：2017-06-19

申请人： AERIE PHARMACEUTICALS, INC.

发明人： Casey Kopczynski ,  Cheng-Wen Lin ,  Jill Marie Sturdivant ,  Mitchell A. deLong

IPC分类号： A61K31/472 ,  C07D409/12 ,  C07D217/22 ,  A61K31/557 ,  A61K31/5575 ,  A61K9/00 ,  A61K9/08 ,  A61K31/559 ,  A61K31/4725

CPC分类号： A61K31/472 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/4725 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/559 ,  A61K47/54 ,  A61K47/55 ,  C07D217/22 ,  C07D409/12 ,  A61K2300/00

摘要： Described herein are compounds and compositions for treating glaucoma and/or reducing introcular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

公开(公告)号：US09765065B2

公开(公告)日：2017-09-19

申请号：US15425470

申请日：2017-02-06

申请人： ALLERGAN, INC.

发明人： David W. Old ,  Vinh X. Ngo ,  Mark Holoboski ,  Mari Posner

IPC分类号： A61K31/381 ,  A61K31/38 ,  A61K31/41 ,  C07D333/10 ,  C07D409/08 ,  C07D333/40 ,  C07D277/56

CPC分类号： C07D409/08 ,  A47G19/06 ,  A61K31/38 ,  A61K31/381 ,  A61K31/41 ,  A61K31/5575 ,  A61K31/559 ,  C07C405/00 ,  C07C2601/08 ,  C07D257/04 ,  C07D277/56 ,  C07D333/10 ,  C07D333/40

摘要： Disclosed herein are compounds having formula (I) wherein a dashed line represents the presence or adsence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ester thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis —CH2CH═CH—(CH2)3—, or —CH2C═C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o—, wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 —CH2— may be replaced by S or O, and 1 —CH2—CH2— may be replaced by —CH═CH— or —C≡C—; U1 and U2 are independently selected from —H, ═O, —OH, —F, —Cl, and —CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.

公开(公告)号：US20170239268A1

公开(公告)日：2017-08-24

申请号：US15448805

申请日：2017-03-03

申请人： Novartis AG

发明人： David Archer Ellis ,  Lukas Scheibler ,  Najam A. Sharif

IPC分类号： A61K31/5575

CPC分类号： A61K31/5575 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/559 ,  A61K45/06 ,  C07C205/49 ,  C07D295/28 ,  A61K2300/00

摘要： Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed. Such compositions comprise an effective amount of prostaglandin conjugates or derivatives of the present invention.

公开(公告)号：US20170144999A1

公开(公告)日：2017-05-25

申请号：US15425470

申请日：2017-02-06

申请人： ALLERGAN, INC.

发明人： David W. Old ,  Vinh X. Ngo ,  Mark Holoboski ,  Mari Posner

IPC分类号： C07D409/08 ,  C07D277/56 ,  C07D333/40

CPC分类号： C07D409/08 ,  A47G19/06 ,  A61K31/38 ,  A61K31/381 ,  A61K31/41 ,  A61K31/5575 ,  A61K31/559 ,  C07C405/00 ,  C07C2601/08 ,  C07D257/04 ,  C07D277/56 ,  C07D333/10 ,  C07D333/40

摘要： Disclosed herein are compounds having formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ester thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis-CH2CH═CH—(CH2)3—, or —CH2C═C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o—, wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 —CH2— may be replaced by S or O, and 1 —CH2—CH2— may be replaced by —CH═CH— or —C≡C—; U1 and U2 are independently selected from —H, ═O, —OH, —F, —Cl, and —CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.

公开(公告)号：US09616017B2

公开(公告)日：2017-04-11

申请号：US15135925

申请日：2016-04-22

申请人： Allergan, Inc.

发明人： Anuradha V. Gore ,  Sai Shankar ,  Sukhon Likitlersuang ,  Chetan P. Pujara ,  Sesha Neervannan

IPC分类号： A61K31/568 ,  A61K38/13 ,  A61K31/416 ,  A61K31/4025 ,  A61P27/02 ,  A61K9/00 ,  A61K47/34 ,  A61K9/08 ,  A61K31/417 ,  A61K31/559

CPC分类号： A61K38/13 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/4025 ,  A61K31/417 ,  A61K31/559 ,  A61K31/568 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/186 ,  A61K47/26 ,  A61K47/34 ,  A61K47/40

摘要： Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.

公开(公告)号：US09591935B2

公开(公告)日：2017-03-14

申请号：US12667197

申请日：2008-06-30

申请人： David W. Old ,  Vinh X. Ngo ,  Mark Holoboski ,  Mari Posner

发明人： David W. Old ,  Vinh X. Ngo ,  Mark Holoboski ,  Mari Posner

IPC分类号： A61K31/38 ,  A61K31/381 ,  A61K31/41 ,  C07D333/10 ,  A47G19/06

CPC分类号： C07D409/08 ,  A47G19/06 ,  A61K31/38 ,  A61K31/381 ,  A61K31/41 ,  A61K31/5575 ,  A61K31/559 ,  C07C405/00 ,  C07C2601/08 ,  C07D257/04 ,  C07D277/56 ,  C07D333/10 ,  C07D333/40

摘要： Disclosed herein are compounds having the formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ether thereof; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis —CH2CH═CH—(CH2)3—, or —CH2C═C—(CH2)3—, wherein 1 or 2 carbon atoms may be replaced by S or O; or A is —(CH2)m—Ar—(CH2)o— wherein Ar is interarylene or heterointerarylene, the sum of m and o is 1, 2, 3, or 4, and wherein 1 —CH2— may be replaced by S or O, and 1 —CH2—CH2— may be replaced by —CH═CH— or —C≡C—; U1 and U2 are independently selected from —H, ═O, —OH, —F, —Cl, and —CN; and B is aryl or heteroaryl, for use as acular hypotensive agent.

摘要翻译： 本文公开了具有式（I）的化合物，其中虚线表示键的存在或不存在; Y是有机酸官能团，或其酰胺或酯; 或Y为羟甲基或其醚; 或Y为四唑基官能团; A是 - （CH 2）6 - ，顺式-CH 2 CH = CH-（CH 2）3 - 或-CH 2C≡C-（CH 2）3 - ，其中1或2个碳原子可被S或O取代; 或A是 - （CH 2）m -Ar-（CH 2）o-，其中Ar是亚芳基或杂亚环烷基，m和o的总和是1,2,3或4，并且其中1 -CH 2可以被S 或O和1 -CH 2 -CH 2 - 可以被-CH = CH-或-C≡C-取代; U1和U2独立地选自-H，= O，-OH，-F，-Cl和-CN; 和B是芳基或杂芳基，用作眼压降低剂。